Mapping RNA: An LC-MS Exploration

Advancements in RNA analysis provide critical insights into drug design, stability, purity, and molecular integrity. In this webinar, BioSpring will highlight its implementation of Waters' latest RNA solutions and discuss the analytical benefits these new tools provide.

Register Free: https://www.biopharminternational.com/bp_w/mapping-RNA

Event Overview:

  Recent advancements in RNA analysis provide critical insights into drug design, stability, purity, and molecular integrity of RNA drug candidates. To analyze larger therapeutic RNAs by liquid chromatography-mass spectrometry (LC-MS), they must be broken down into smaller fragments. Novel RNA endonucleases, high-purity mobile phase reagents, and integrated data processing workflows now simplify and automate these tasks, making LC-MS assays more accessible. These innovations lower the adoption barrier for LC-MS, accelerating the development and market readiness of RNA-based therapeutics.

This webinar will feature insights from BioSpring, a leading European oligonucleotide manufacturer. BioSpring will highlight its implementation of Waters' latest RNA solutions and discuss the analytical benefits these new tools have provided.

Key Learning Objectives:

• Learn about a comprehensive set of tools for LC-MS analysis of large RNA molecules, including enzymes, reagents, and informatics tools
• Understand a novel method for evaluating ribonuclease (RNase) specificity with custom oligonucleotide probes
• Learn about method considerations for sgRNA and mRNA digestion and data analysis

Who Should Attend:

• Scientists, technicians, and managers charged with analyzing therapeutic RNA samples
• Others from pharmaceutical and contract organizations looking to develop and commercialize these molecules and better understand the analytical challenges of producing high-quality products and processes
  
  

Speaker:

Michael Ruehl
Senior QC Researcher
BioSpring

Michael Ruehl studied pharmaceutical sciences from 2010 to 2015 at the University of Frankfurt. From 2015 to 2019, he worked in the Karas group on covalently binding enzyme inhibitors and protein and peptide mass spectrometry (MS). After receiving his PhD in pharmaceutical chemistry, he started working at BioSpring as a lab head for bioanalytics, and is now heading the analytical research and development department.

Register Free: https://www.biopharminternational.com/bp_w/mapping-RNA